SUROVATAMIG
UNII 3QW12I37H1

Substance Identification & Data

This profile provides standardized clinical and technical data for Surovatamig, uniquely identified by the FDA Unique Ingredient Identifier (UNII) 3QW12I37H1.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number 2892667-02-4 and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

3QW12I37H1

CAS Registry Number

2892667-02-4

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

SUROVATAMIG

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C178577

National Cancer Institute reference terminology for clinical and research data.

INN ID

13199

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

OP-138

Identifier assigned by the United States Adopted Names Council.

Substance Type

Surovatamig

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Surovatamig. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

Surovatamig

Common Names & Synonyms

H-gamma4 heavy chain anti-CD3D/CD3E dimer, Homo sapiens (1-450) [VH (Homo sapiens IGHV3-9*01 (100%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.16] (26-33.51-58.97-112)) (1-123)-Homo sapiens IGHG4*01 nG4m(a) CH2 L92, G4v5 h P10, G4v4 CH2 A1.3, A1.2, G4v32 CH3 W22 (knob) (CH1 (124-221), hinge 1-12 S10>P (231) (222-233), CH2 F1.3>A (237), L1.2>A (238), L92 (312) (234-343), CH3 T22>W (369) (344-448), CHS (449-450)) (124-450)], (137-214')-disulfide with L-kappa light chain anti-CD3D-CD3E Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV3-15*01 (100%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; VH-G4(h-CH2-CH3) heavy chain anti-CD19, humanized and Homo sapiens (1''-345'') [humanized VH (Homo sapiens IGHV3-7*01 (91.8%) -(IGHD) -IGHJ4*01 (92.9%) W118>R (106''), CDR-IMGT [8.8.9] (26''-33''.51''-58''.97''-105'')) (1''-116'')-Homo sapiens IGHG4*01 h-CH2-CH3, G4v5 h P10,nG4m(a) CH2 L92, G4v4 CH2 A1.3, A1.2, G1v33 CH3 S22, A24, V86 (hole) (hinge 1-12 S10>P (126'') (117''-128''), CH2 F1.3>A (132''), L1.2>A (133''), L92 (207'') (129''-238''), CH3 T22>S (264''), L24>A (266''), Y86>V (305'') (239''-343''), CHS (344''-345'')) (117''-345'')]; dimer (229-124'':232-127'')-bisdisulfide, produced in a cell line from Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa

Immunoglobulin G4 [231-proline,237-alanine,238-alanine,369-tryptophan], bispecific, anti-(human CD3 antigen) (human monoclonal AZD0486 γ4-chain) disulfide with human monoclonal AZD0486 κ-chain, (229→124′),(232→127′)-bis(disulfide) with immunoglobulin [126-proline,132-alanine,133-alanine] anti-(CD19 antigen) (human single-domain variable region) fusion protein with 219-447-immunoglobulin G4 [228-proline,234-alanine,235-alanine,366-serine,368-alanine,407-valine] (human monoclonal AZD0486 γ4-chain)

SUROVATAMIG [USAN]

Surovatamig [WHO-DD]

immunoglobulin (H-gamma4_L-kappa)_VH-G4(h-CH2-CH3), anti-[Homo sapiens CD3D (CD3 delta) and CD3E (CD3 epsilon, Leu-4) dimer] and anti-[Homo sapiens CD19 (B lymphocyte surface antigen B4, Leu-12)], Homo sapiens and humanized monoclonal antibody asymetric, bispecific, bivalent

surovatamig [INN]